Multiparticulate controlled release selective serotonin reuptake inhibitor formulations
View Patent ↗A multiparticulate controlled release selective serotonin reuptate inhibitor (SSRI) formulation for oral administration is provided. The formulation includes particles of an SSRI or a pharmaceutically acceptable salt thereof, which are coated with a rate-controlling polymer that allows controlled release of the SSRI over a period of not less than about 12 hours after oral administration. The rate controlling polymer includes a film-forming water-insoluble polymer, or a mixture of a film-forming water-insoluble polymer and a film-forming water-soluble polymer.
1. A multiparticulate controlled release selective serotonin reuptake inhibitor (SSRI) composition for oral administration comprising two quantities of particles, each of the particles comprising
(i) an inert non-pareil core,
(ii) an SSRI layer comprising fluvoxamine or a pharmaceutically-acceptable salt thereof disposed over the inert core, and
(iii) a coating of a rate-controlling polymeric acrylate, methacrylate lacquer, or a mixture thereof disposed over the fluvoxamine,
wherein the composition allows the controlled release of the fluvoxamine over a period of not less than about 12 hours following oral administration, wherein the rate-controlling polymeric acrylate or methacrylate lacquer coating of the first quantity of particles is present in a first amount, and the rate-controlling polymeric acrylate or methacrylate lacquer coating of the second quantity of particles is present in a second amount that is different from the first amount, and wherein the fluvoxamine release rate from the composition exhibits the following in vitro dissolution pattern when measured using a USP type II dissolution apparatus (paddle) according to US Pharmacopeia XXII in 0.05 M phosphate buffer at pH 6.8:
(a) no more than about 15% of the total fluvoxamine is released after 0.5 of an hour of measurement in the apparatus;
(b) no more than about 25% of the total fluvoxamine is released after 1 hour of measurement in the apparatus;
(c) between about 20% and 75% of the total fluvoxamine is released after 2 hours of measurement in the apparatus;
(d) not less than about 75% of the total fluvoxamine is released after 4 hours of measurement in the apparatus; and
(e) not less than about 85% of the total fluvoxamine is released after 6 hours of measurement in the apparatus.
2. The composition according to claim 1 wherein the coating is the polymeric acrylate lacquer.
3. The composition according to claim 1 wherein the coating is the methacrylate lacquer.
4. The composition according to claim 1 wherein the coating is a lacquer which contains a mixture of acrylate and methacrylate.
5. The composition according to claim 1 wherein the coating is an acrylic resin comprising a copolymer of acrylic and methacrylic acid esters having a low content of quaternary ammonium groups.
6. The composition of claim 1 wherein the rate-controlling coating comprises an ammonio methacrylate lacquer and a plasticizer, the combined amount of the ammonio methacrylate lacquer and the plasticizer in the membrane coating being in an amount of from about 4% to about 15% of the weight of the particle.
7. The composition of claim 6 wherein the combined amount of the ammonio methacrylate lacquer and the plasticizer in the rate controlling coating of the first or second quantity of particles is in an amount of 4%, 6%, 8%, 10%, 12%, or 15% of the weight of the particle.
8. The composition of claim 1 , wherein the controlled-release of the fluvoxamine is effective in supplying fluvoxamine to the blood of a patient such that, following a single application of the composition to the patient, the amount of circulating fluvoxamine (AUC 0-∞ ) in the blood serum of the patient is about 128 to about 1,175 ng/ml.h.
9. A multiparticulate controlled release selective serotonin reuptake inhibitor (SSRI) composition for oral administration comprising two quantities of particles, each of the particles comprising
(i) an inert non-pareil core,
(ii) an SSRI layer comprising fluvoxamine or a pharmaceutically-acceptable salt thereof disposed over the inert core, and
(iii) a coating of a rate-controlling polymeric acrylate, methacrylate lacquer, or a mixture thereof disposed over the fluvoxamine,
wherein the composition allows the controlled release of the fluvoxamine over a period of not less than about 12 hours following oral administration, wherein the rate-controlling polymeric acrylate or methacrylate lacquer coating of the first quantity of particles is present in a first amount, and the rate-controlling polymeric acrylate or methacrylate lacquer coating of the second quantity of particles is present in a second amount that is different from the first amount, and wherein the fluvoxamine release rate from the composition exhibits the following in vitro dissolution pattern when measured using a USP type II dissolution apparatus (paddle) according to US Pharmacopeia XXII in 0.05 M phosphate buffer at pH 6.8:
(a) no more than about 20% of the total fluvoxamine is released after 4 hours of measurement in the apparatus;
(b) no more than about 45% of the total fluvoxamine is released after 6 hours of measurement in the apparatus;
(c) between about 45% and 80% of the total fluvoxamine is released after 8 hours of measurement in the apparatus;
(d) not less than about 70% of the total fluvoxamine is released after 10 hours of measurement in the apparatus; and
(c) not less than about 80% of the total fluvoxamine is released after 12 hours of measurement in the apparatus.
10. The composition of claim 9 , wherein the coating is the polymeric acrylate lacquer.
11. The composition of claim 9 , wherein the coating is the methacrylate lacquer.
12. The composition of claim 9 , wherein the coating is a lacquer which contains a mixture of acrylate and methacrylate.
13. The composition of claim 9 , wherein the coating is an acrylic resin comprising a copolymer of acrylic and methacrylic acid esters having a low content of quaternary ammonium groups.
14. The composition of claim 9 , wherein the rate-controlling coating comprises an ammonio methacrylate lacquer and a plasticizer, the combined amount of the ammonio methacrylate lacquer and the plasticizer in the membrane coating being in an amount of from about 4% to about 15% of the weight of the particle.
15. The composition of claim 14 , wherein the combined amount of the ammonio methacrylate lacquer and the plasticizer in the rate controlling coating of the first or second quantity of particles is in an amount of 4%, 6%, 8%, 10%, 12%, or 15% of the weight of the particle.
16. The composition of claim 9 , wherein the controlled-release of the fluvoxamine is effective in supplying fluvoxamine to the blood of a patient such that, following a single application of the composition to the patient, the amount of circulating fluvoxamine (AUC 0-∞ ) in the blood serum of the patient is about 128 to about 1,175 ng/ml.h.
17. A multiparticulate controlled release selective serotonin reuptake inhibitor (SSRI) composition for oral administration comprising two quantities of particles, each of the particles comprising
(i) an inert non-pareil core,
(ii) an SSRI layer comprising fluvoxamine or a pharmaceutically-acceptable salt thereof disposed over the inert core, and
(iii) a coating of a rate-controlling polymeric acrylate, methacrylate lacquer, or a mixture thereof disposed over the fluvoxamine,
wherein the composition allows the controlled release of the fluvoxamine over a period of not less than about 12 hours following oral administration, wherein the rate-controlling polymeric acrylate or methacrylate lacquer coating of the first quantity of particles is present in a first amount, and the rate-controlling polymeric acrylate or methacrylate lacquer coating of the second quantity of particles is present in a second amount that is different from the first amount, and wherein the fluvoxamine release rate from the composition exhibits the following in vitro dissolution pattern when measured using a USP type II dissolution apparatus (paddle) according to US Pharmacopeia XXII in 0.05 M phosphate buffer at pH 6.8:
(a) no more than 20% of the total fluvoxamine is released after 1 hour of measurement in the apparatus;
(b) no more than 60% of the total fluvoxamine is released after 2 hours of measurement in the apparatus;
(c) not less than 20% of the total fluvoxamine is released after 4 hours of measurement in the apparatus;
(d) not less than 35% of the total fluvoxamine is released after 6 hours of measurement in the apparatus;
(e) not less than 50% of the total fluvoxamine is released after 8 hours of measurement in the apparatus;
(f) not less than 70% of the total fluvoxamine is released after 10 hours of measurement in the apparatus; and
(g) not less than 75% of the total fluvoxamine is released after 12 hours of measurement in the apparatus.
18. The composition of claim 17 , wherein the coating is the polymeric acrylate lacquer.
19. The composition of claim 17 , wherein the coating is the methacrylate lacquer.
20. The composition of claim 17 , wherein the coating is a lacquer which contains a mixture of acrylate and methacrylate.
21. The composition of claim 17 , wherein the coating is an acrylic resin comprising a copolymer of acrylic and methacrylic acid esters having a low content of quaternary ammonium groups.
22. The composition of claim 17 , wherein the rate-controlling coating comprises an ammonio methacrylate lacquer and a plasticizer, the combined amount of the ammonio methacrylate lacquer and the plasticizer in the membrane coating being in an amount of from about 4% to about 15% of the weight of the particle.
23. The composition of claim 22 , wherein the combined amount of the ammonio methacrylate lacquer and the plasticizer in the rate controlling coating of the first or second quantity of particles is in an amount of 4%, 6%, 8%, 10%, 12%, or 15% of the weight of the particle.
24. The composition of claim 17 , wherein the controlled-release of the fluvoxamine is effective in supplying fluvoxamine to the blood of a patient such that, following a single application of the composition to the patient, the amount of circulating fluvoxamine (AUC 0-∞ ) in the blood serum of the patient is about 128 to about 1,175 ng/ml.h.
25. A multiparticulate controlled release selective serotonin reuptake inhibitor (SSRI) composition for oral administration comprising two quantities of particles, each of the particles comprising
(i) an inert non-pareil core,
(ii) an SSRI layer comprising fluvoxamine or a pharmaceutically-acceptable salt thereof disposed over the inert core, and
(iii) a coating of a rate-controlling polymeric acrylate, methacrylate lacquer, or a mixture thereof disposed over the fluvoxamine,
wherein the composition allows the controlled release of the fluvoxamine over a period of not less than about 12 hours following oral administration, wherein the rate-controlling polymeric acrylate or methacrylate lacquer coating of the first quantity of particles is present in a first amount, and the rate-controlling polymeric acrylate or methacrylate lacquer coating of the second quantity of particles is present in a second amount that is different from the first amount, and wherein the fluvoxamine release rate from the composition exhibits the following in vitro dissolution pattern when measured using a USP type II dissolution apparatus (paddle) according to US Pharmacopeia XXII in 0.05 M phosphate buffer at pH 6.8:
(a) no more than about 20% of the total fluvoxamine is released after 1 hour of measurement in the apparatus;
(b) no more than about 45% of the total fluvoxamine is released after 2 hours of measurement in the apparatus;
(c) between about 20% and about 70% of the total fluvoxamine is released after 4 hours of measurement in the apparatus;
(d) between about 35% and about 85% of the total fluvoxamine is released after 6 hours of measurement in the apparatus;
(e) not less than about 50% of the total fluvoxamine is released after 8 hours of measurement in the apparatus;
(f) not less than about 70% of the total fluvoxamine is released after 10 hours of measurement in the apparatus; and
(g) not less than about 75% of the total fluvoxamine is released after 12 hours of measurement in the apparatus.
26. The composition of claim 25 , wherein the coating is the polymeric acrylate lacquer.
27. The composition of claim 25 , wherein the coating is the methacrylate lacquer.
28. The composition of claim 25 , wherein the coating is a lacquer which contains a mixture of acrylate and methacrylate.
29. The composition of claim 25 , wherein the coating is an acrylic resin comprising a copolymer of acrylic and methacrylic acid esters having a low content of quaternary ammonium groups.
30. The composition of claim 25 , wherein the rate-controlling coating comprises an ammonio methacrylate lacquer and a plasticizer, the combined amount of the ammonio methacrylate lacquer and the plasticizer in the membrane coating being in an amount of from about 4% to about 15% of the weight of the particle.
31. The composition of claim 30 , wherein the combined amount of the ammonio methacrylate lacquer and the plasticizer in the rate controlling coating of the first or second quantity of particles is in an amount of 4%, 6%, 8%, 10%, 12%, or 15% of the weight of the particle.
32. The composition of claim 25 , wherein the controlled-release of the fluvoxamine is effective in supplying fluvoxamine to the blood of a patient such that, following a single application of the composition to the patient, the amount of circulating fluvoxamine (AUC 0-∞ ) in the blood serum of the patient is about 128 to about 1,175 ng/ml.h.
33. A multiparticulate controlled release selective serotonin reuptake inhibitor (SSRI) composition for oral administration comprising two quantities of particles, each of the particles comprising
(i) an inert non-pareil core,
(ii) an SSRI layer comprising fluvoxamine or a pharmaceutically-acceptable salt thereof disposed over the inert core, and
(iii) a coating of a rate-controlling polymeric acrylate, methacrylate lacquer, or a mixture thereof disposed over the fluvoxamine,
wherein the composition allows the controlled release of the fluvoxamine over a period of not less than about 12 hours following oral administration, wherein the rate-controlling polymeric acrylate or methacrylate lacquer coating of the first quantity of particles is present in a first amount, and the rate-controlling polymeric acrylate or methacrylate lacquer coating of the second quantity of particles is present in a second amount that is different from the first amount, and wherein the fluvoxamine release rate from the composition exhibits the following in vitro dissolution pattern when measured using a USP type II dissolution apparatus (paddle) according to US Pharmacopeia XXII in 0.05 M phosphate buffer at pH 6.8:
(a) no more than about 50% of the total fluvoxamine is released after 2 hours of measurement in the apparatus;
(b) not less than about 35% of the total fluvoxamine is released after 6 hours of measurement in the apparatus; and
(c) not less than about 80% of the total fluvoxamine is released after 22 hours of measurement in the apparatus.
34. The composition of claim 33 , wherein the coating is the polymeric acrylate lacquer.
35. The composition of claim 33 , wherein the coating is the methacylate lacquer.
36. The composition of claim 33 , wherein the coating is a lacquer which contains a mixture of acrylate and methacrylate.
37. The composition of claim 34 , wherein the coating is an acrylic resin comprising a copolymer of acrylic and methacrylic acid esters having a low content of quaternary ammonium groups.
38. The composition of claim 33 , wherein the rate-controlling coating comprises an ammonio methacrylate lacquer and a plasticizer, the combined amount of the ammonio methacrylate lacquer and the plasticizer in the membrane coating being in an amount of from about 4% to about 15% of the weight of the particle.
39. The composition of claim 38 , wherein the combined amount of the ammonio methacrylate lacquer and the plasticizer in the rate controlling coating of the first or second quantity of particles is in an amount of 4%, 6%, 8%, 10%, 12%, or 15% of the weight of the particle.
40. The composition of claim 33 , wherein the controlled-release of the fluvoxamine is effective in supplying fluvoxamine to the blood of a patient such that, following a single application of the composition to the patient, the amount of circulating fluvoxamine (AUC 0-∞ ) in the blood serum of the patient is about 128 to about 1,175 ng/ml.h.
41. A method for the treatment of depression or obsessive compulsive disorder treatable with an SSRI, comprising administering to a patient suffering from one of the conditions a therapeutically effective amount of a multiparticulate controlled release selective serotonin reuptake inhibitor (SSRI) composition for oral administration comprising two quantities of particles, each of the particles comprise
(i) an inert non-pareil core,
(ii) an SSRI layer comprising fluvoxamine or a pharmaceutically-acceptable salt thereof disposed over the inert core, and
(iii) a coating of a rate-controlling polymeric acrylate, methacrylate lacquer, or a mixture thereof disposed over the fluvoxamine,
wherein the composition allows the controlled release of the fluvoxamine over a period of not less than about 12 hours following oral administration, and wherein the rate-controlling polymeric acrylate or methacrylate lacquer coating of the first quantity of particles is present in a first amount, and the rate-controlling polymeric acrylate or methacrylate lacquer coating of the second quantity of particles is present in a second amount that is different from the first amount, and wherein the fluvoxamine release rate from the composition exhibits the following in vitro dissolution pattern when measured using a USP type II dissolution apparatus (paddle) according to US Pharmacopeia XXII in 0.05 M phosphate buffer at pH 6.8:
(a) no more than about 15% of the total fluvoxamine is released after 0.5 of an hour of measurement in the apparatus;
(b) no more than about 25% of the total fluvoxamine is released after 1 hour of measurement in the apparatus;
(c) between about 20% and 75% of the total fluvoxamine is released after 2 hours of measurement in the apparatus;
(d) not less than about 75% of the total fluvoxamine is released after 4 hours of measurement in the apparatus; and
(c) not less than about 85% of the total fluvoxamine is released after 6 hours of measurement in the apparatus.
42. A method for the treatment of depression or obsessive compulsive disorder treatable with an SSRI, comprising administering to a patient suffering from one of the conditions a therapeutically effective amount of a multiparticulate controlled release selective serotonin reuptake inhibitor (SSRI) composition for oral administration comprising two quantities of particles, each of the particles comprise
(i) an inert non-pareil core,
(ii) an SSRI layer comprising fluvoxamine or a pharmaceutically-acceptable salt thereof disposed over the inert core, and
(iii) a coating of a rate-controlling polymeric acrylate, methacrylate lacquer, or a mixture thereof disposed over the fluvoxamine,
wherein the composition allows the controlled release of the fluvoxamine over a period of not less than about 12 hours following oral administration, and wherein the rate-controlling polymeric acrylate or methacrylate lacquer coating of the first quantity of particles is present in a first amount, and the rate-controlling polymeric acrylate or methacrylate lacquer coating of the second quantity of particles is present in a second amount that is different from the first amount, and wherein the fluvoxamine release rate from the composition exhibits the following in vitro dissolution pattern when measured using a USP type II dissolution apparatus (paddle) according to US Pharmacopeia XXII in 0.05 M phosphate buffer at pH 6.8:
(a) no more than about 20% of the total fluvoxamine is released after 4 hours of measurement in the apparatus;
(b) no more than about 45% of the total fluvoxamine is released after 6 hours of measurement in the apparatus;
(c) between about 45% and 80% of the total fluvoxamine is released after 8 hours of measurement in the apparatus;
(d) not less than about 70% of the total fluvoxamine is released after 10 hours of measurement in the apparatus; and
(e) not less than about 80% of the total fluvoxamine is released after 12 hours of measurement in the apparatus.
43. A method for the treatment of depression or obsessive compulsive disorder treatable with an SSRI, comprising administering to a patient suffering from one of the conditions a therapeutically effective amount of a multiparticulate controlled release selective serotonin reuptake inhibitor (SSRI) composition for oral administration comprising two quantities of particles, each of the particles comprise
(i) an inert non-pareil core,
(ii) an SSRI layer comprising fluvoxamine or a pharmaceutically-acceptable salt thereof disposed over the inert core, and
(iii) a coating of a rate-controlling polymeric acrylate, methacrylate lacquer, or a mixture thereof disposed over the fluvoxamine,
wherein the composition allows the controlled release of the fluvoxamine over a period of not less than about 12 hours following oral administration, and wherein the rate-controlling polymeric acrylate or methacrylate lacquer coating of the first quantity of particles is present in a first amount, and the rate-controlling polymeric acrylate or methacrylate lacquer coating of the second quantity of particles is present in a second amount that is different from the first amount, and wherein the fluvoxamine release rate from the composition exhibits the following in vitro dissolution pattern when measured using a USP type II dissolution apparatus (paddle) according to US Pharmacopeia XXII in 0.05 M phosphate buffer at pH 6.8:
(a) no more than 20% of the total fluvoxamine is released after 1 hour of measurement in the apparatus;
(b) no more than 60% of the total fluvoxamine is released after 2 hours of measurement in the apparatus;
(c) not less than 20% of the total fluvoxamine is released after 4 hours of measurement in the apparatus;
(d) not less than 35% of the total fluvoxamine is released after 6 hours of measurement in the apparatus;
(e) not less than 50% of the total fluvoxamine is released after 8 hours of measurement in the apparatus;
(f) not less than 70% of the total fluvoxamine is released after 10 hours of measurement in the apparatus; and
(g) not less than 75% of the total fluvoxamine is released after 12 hours of measurement in the apparatus.
44. A method for the treatment of depression or obsessive compulsive disorder treatable with an SSRI, comprising administering to a patient suffering from one of the conditions a therapeutically effective amount of a multiparticulate controlled release selective serotonin reuptake inhibitor (SSRI) composition for oral administration comprising two quantities of particles, each of the particles comprise
(i) an inert non-pareil core,
(ii) an SSRI layer comprising fluvoxamine or a pharmaceutically-acceptable salt thereof disposed over the inert core, and
(iii) a coating of a rate-controlling polymeric acrylate, methacrylate lacquer, or a mixture thereof disposed over the fluvoxamine,
wherein the composition allows the controlled release of the fluvoxamine over a period of not less than about 12 hours following oral administration, and wherein the rate-controlling polymeric acrylate or methacrylate lacquer coating of the first quantity of particles is present in a first amount, and the rate-controlling polymeric acrylate or methacrylate lacquer coating of the second quantity of particles is present in a second amount that is different from the first amount, and wherein the fluvoxamine release rate from the composition exhibits the following in vitro dissolution pattern when measured using a USP type II dissolution apparatus (paddle) according to US Pharmacopeia XXII in 0.05 M phosphate buffer at pH 6.8:
(a) no more than about 20% of the total fluvoxamine is released after 1 hour of measurement in the apparatus;
(b) no more than about 45% of the total fluvoxamine is released after 2 hours of measurement in the apparatus;
(c) between about 20% and about 70% of the total fluvoxamine is released after 4 hours of measurement in the apparatus;
(d) between about 35% and about 85% of the total fluvoxamine is released after 6 hours of measurement in the apparatus;
(e) not less than about 50% of the total fluvoxamine is released after 8 hours of measurement in the apparatus;
(f) not less than about 70% of the total fluvoxamine is released after 10 hours of measurement in the apparatus; and
(g) not less than about 75% of the total fluvoxamine is released after 12 hours of measurement in the apparatus.
45. A method for the treatment of depression or obsessive compulsive disorder treatable with an SSRI, comprising administering to a patient suffering from one of the conditions a therapeutically effective amount of a multiparticulate controlled release selective serotonin reuptake inhibitor (SSRI) composition for oral administration comprising two quantities of particles, each of the particles comprise
(i) an inert non-pareil core,
(ii) an SSRI layer comprising fluvoxamine or a pharmaceutically-acceptable salt thereof disposed over the inert core, and
(iii) a coating of a rate-controlling polymeric acrylate, methacrylate lacquer, or a mixture thereof disposed over the fluvoxamine,
wherein the composition allows the controlled release of the fluvoxamine over a period of not less than about 12 hours following oral administration, and wherein the rate-controlling polymeric acrylate or methacrylate lacquer coating of the first quantity of particles is present in a first amount, and the rate-controlling polymeric acrylate or methacrylate lacquer coating of the second quantity of particles is present in a second amount that is different from the first amount, and wherein the fluvoxamine release rate from the composition exhibits the following in vitro dissolution pattern when measured using a USP type II dissolution apparatus (paddle) according to US Pharmacopeia XXII in 0.05 M phosphate buffer at pH 6.8:
(a) no more than about 50% of the total fluvoxamine is released after 2 hours of measurement in the apparatus;
(b) not less than about 35% of the total fluvoxamine is released after 6 hours of measurement in the apparatus; and
(c) not less than about 80% of the total fluvoxamine is released after 22 hours of measurement in the apparatus.